Pilot studies for development of an HIV subtype panel for surveillance of global diversity

AIDS Research and Human Retroviruses

Volumn 28, Issue 6, 2012, Pages 594-606

  Manak, Mark ^a,b   Sina, Silvana ^b   Anekella, Bharathi ^a   Hewlett, Indira ^c   Sanders Buell, Eric ^b   Ragupathy, Viswanath ^c   Kim, Jerome ^d   Vermeulen, Marion ^e   Stramer, Susan L ^f   Sabino, Ester ^g   Grabarczyk, Piotr ^h   Michael, Nelson ^d   Peel, Sheila ^d   Garrett, Patricia ^a   Tovanabutra, Sodsai ^b   Busch, Michael P ⁱ   Schito, Marco ^j  

^a Genomics Collaborative   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e SOUTH AFRICAN NATIONAL BLOOD SERVICE   (South Africa)

^f AMERICAN RED CROSS   (United States)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

ⁱ BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^j NATIONAL INSTITUTES OF HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; PHYTOHEMAGGLUTININ; VIRUS ENVELOPE PROTEIN;

ARTICLE; BLOOD SAMPLING; CELL STIMULATION; COCULTURE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SURVEILLANCE; ENVELOPE GENE; ENZYME IMMUNOASSAY; EPIDEMIC; FOOD AND DRUG ADMINISTRATION; GENE SEQUENCE; HIV TEST; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; MAJOR CLINICAL STUDY; MICROBIAL DIVERSITY; NONHUMAN; NUCLEIC ACID ANALYSIS; NUCLEOTIDE SEQUENCE; PANEL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SCREENING; VIRUS ISOLATION; VIRUS LOAD; VIRUS TYPING; WESTERN BLOTTING;

AIDS VACCINES; ALGORITHMS; BRAZIL; CELLS, CULTURED; GENOME, VIRAL; HIV ANTIBODIES; HIV SEROPOSITIVITY; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PHYLOGENY; PILOT PROJECTS; POLAND; POPULATION SURVEILLANCE; SOUTH AFRICA; UNITED STATES;

EID: 84861851364     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0271     Document Type: Article

References (42)

1. AIDS Epidemic Update: November 2009. www.unaids.org/ globalreport/global- report.htm.
2. LANL HIV Sequence Database, www.HIV.lanl.gov. 2011: Los Alamos.
3. Schmidt M, et al.: First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion 2009;49(9):1836-1844.
4. Tebit DM and Arts EJ: Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis 2011;11(1):45-56.
5. Taylor BS and Hammer SM: The challenge of HIV-1 subtype diversity. N Engl J Med 2008;359(18):1965-1966.
6. Sezgin E, et al.: Effect of host genetics on incidence of HIV neuroretinal disorder in patients with AIDS. J Acquir Immune Defic Syndr 2010;54(4):343-351.
7. Buonaguro L, Tornesello ML, and Buonaguro FM: Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: Pathogenetic and therapeutic implications. J Virol 2007;81(19):10209-10219.
8. Soriano V and De Mendoza C: Update on HIV viral-load assays: New technologies and testing in resource-limited settings. Future Virol 2009;4(5):423-430.
9. Edelmann A, et al.: Improvement of an ultrasensitive human immunodeficiency virus type 1 real-time reverse transcriptase- polymerase chain reaction targeting the long terminal repeat region. Transfusion 2010;50(3):685-692.
10. Henquell C, et al.: Difficulties in diagnosing group O human immunodeficiency virus type 1 acute primary infection. J Clin Microbiol 2008;46(7):2453-2456.
11. Foglieni B, et al.: A cluster of human immunodeficiency virus Type 1 recombinant form escaping detection by commercial genomic amplification assays. Transfusion 2011; 51(4):719-730.
12. Nubling CM, et al.: Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions. Transfusion 2009;49(9):1850-1858.
13. Church D, et al.: Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections. J Clin Microbiol 2011;49(1):118-124.
14. Kline NE, Schwarzwald H, and Kline MW: False negative DNA polymerase chain reaction in an infant with subtype C human immunodeficiency virus 1 infection. Pediatr Infect Dis J 2002;21(9):885-886.
15. Obaro SK, et al.: Failure of serial human immunodeficiency virus type 1 DNA polymerase chain reactions to identify human immunodeficiency virus type 1 clade A/G. Pediatr Infect Dis J 2005;24(2):183-184.
16. Ntemgwa M, et al.: Discrepancies in assignment of subtype/ recombinant forms by genotyping programs for HIV type 1 drug resistance testing may falsely predict superinfection. AIDS Res Hum Retroviruses 2008;24(7):995-1002.
17. Snoeck J, et al.: Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother 2006;50(2):694-701.
18. Kuritzkes DR: HIV-1 subtype as a determinant of disease progression. J Infect Dis 2008;197(5):638-639.
19. Renjifo B, et al.: Differences in perinatal transmission among human immunodeficiency virus type 1 genotypes. J Hum Virol 2001;4(1):16-25.
20. Baeten JM, et al.: HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007;195(8):1177-1180.
21. Daar ES, et al.: Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis 2007;45(5):643-649.
22. Weiss R, et al.: Acquired immunodeficiency syndrome-related lymphoma: Simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival-results of the German Multicenter Trial. Cancer 2006;106(7):1560-1568.
23. Kaslow RA, Dorak T, and Tang JJ: Influence of host genetic variation on susceptibility to HIV type 1 infection. J Infect Dis 2005;191(Suppl 1):S68-S77.
24. Huang DD, Giesler TA, and Bremer JW: Sequence characterization of the protease and partial reverse transcriptase proteins of the NED panel, an international HIV type 1 subtype reference and standards panel. AIDS Res Hum Retroviruses 2003;19(4):321-328.
25. Brown BK, et al.: Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01-AE, and CRF02-AG, for the development and assessment of candidate vaccines. J Virol 2005;79(10):6089-6101.
26. Keele BF, et al.: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008;105(21):7552-7557.
27. Salazar-Gonzalez JF, et al.: Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009;206(6):1273-1289.
28. Fiebig EW, et al.: Dynamics of HIV viremia and antibody seroconversion in plasma donors: Implications for diagnosis and staging of primary HIV infection. AIDS 2003;17(13): 1871-1879.
29. Erice A, et al.: Sensitive microculture method for isolation of human immunodeficiency virus type 1 from blood leukocytes. J Clin Microbiol 1992;30(2):444-448.
30. Rolland M, et al.: Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 2011;17(3):366-371.
31. Deng W, et al.: DIVEIN: A web server to analyze phylogenies, sequence divergence, diversity, and informative sites. Biotechniques 2010;48(5):405-408.
32. Giorgi EE, et al.: Estimating time since infection in early homogeneous HIV-1 samples using a poisson model. BMC Bioinformatics 2010;11:532.
33. Vodros D and Fenyo EM: Quantitative evaluation of HIV and SIV co-receptor use with GHOST(3) cell assay. Methods Mol Biol 2005;304:333-342.
34. Erali M and Hillyard DR: Evaluation of the ultrasensitive Roche Amplicor HIV-1 monitor assay for quantitation of human immunodeficiency virus type 1 RNA. J Clin Microbiol 1999;37(3):792-795.
35. De Bel A, et al.: Correction of underquantification of human immunodeficiency virus type 1 load with the second version of the Roche Cobas AmpliPrep/Cobas TaqMan assay. J Clin Microbiol 2010;48(4):1337-1342.
36. Elbeik T, et al.: Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5. J Clin Microbiol 2000;38(3):1113-1120.
37. Vella S, et al.: Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment. Antiviral Res 2000;47(3):189-198.
38. PiatakM Jr, et al.: Viral dynamics in primary HIV-1 infection. Lancet 1993;341(8852):1099.
39. Gorry PR, et al.: Isolation of human immunodeficiency virus type 1 from peripheral blood monocytes. Methods Mol Biol 2005;304:25-33.
40. Sourisseau M, et al.: Inefficient human immunodeficiency virus replication in mobile lymphocytes. J Virol 2007;81(2): 1000-1012.
41. Goonetilleke N, et al.: The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009;206(6): 1253-1272.
42. Cuevas MT, et al.: Biological and genetic characterization of HIV type 1 subtype B and nonsubtype B transmitted viruses: Usefulness for vaccine candidate assessment. AIDS Res Hum Retroviruses 2010;26(9):1019-1025.